22.6 C
New York
Saturday, May 28, 2022

BioNano Genomics Inc. (BNGO) Stock plummeting continue today

BioNano Genomics Inc. (BNGO) ‘s stock price dropped -11.23% Yesterday, and the negative trend is keeping its momentum in today’sMarch 25 pre-market session. As of this writing, it has lost -3.77%.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .


Here are the latest updates about BioNano Genomics.

Financial results announcement:

On March 23, 2021, BNGO announced its financial results for the three and twelve months ended December 31, 2020. The results were announced after the market close.

Q4 2020 financial highlights

  • BNGO earned $4.0 million for the fourth quarter of 2020, compared to $2.8 million for the same period in 2019. It beat analyst’s revenue estimate of $3.5 million.
  • Its gross margin was 30% for the fourth quarter of 2020, compared with 39% in the same period in 2019.
  • The company operating expenses were increased to $12.3 million for the fourth quarter of 2020 compared to $8.9 million for the same period in 2019.
  • The company announced a net loss in Q4 of $11.7 million, or around $0.08 per share, which is more than the average analysts estimate of $0.05 per share.

Full-year 2020 financial highlights

  • BNGO revenue declined to $8.5 million for 2020, compared with $10.1 million in 2019.
  • Gross margins for the year ended December 31, 2020, were 33%, consistent with 2019.
  • The company spent $41.3 million in operating expenses for the year ended December 31, 2020, compared to $29.9 million for the same period in 2019
  • As of December 31, 2020, BNGO had cash and cash equivalents of $38.4 million.

BNGO 2021 targets

  • BNGO is looking  for accreditation of Saphyr based LDTs for ALL & FSHD in specific EU markets in the 2nd quarter of 2021
  • The company expects the commercial release of prenatal assays and expansion of the menu of pediatric assays in the third quarter of os 2021.
  • In the fourth quarter of 2021,  BNGOexpects interim results from the pediatric clinical study, Prototype of next-gen high throughput Saphyr.

Participation in the recent investors’ conferences

Bionano Genomics, Inc. (Nasdaq: BNGO) participated virtually at the following investor conference, which held recently

  • Maxim Group’s Emerging Growth Conference, which was held on March 17-19, 2021.

Conclusion: The recent results missed the analyst’s estimates. That’s why its price is declining now, but investors are pretty optimistic that 2021 will be a good year for Bionano. The acquisition of diagnostic services provider Lineagen, the better cash position of the company at the end of fourth-quarter 2020, and expected validation of three of its laboratory-developed tests with billing codes make it an attractive option for the investors. Its stock can start gaining positive momentum in near future and can each to new heights.

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Related Articles


Please enter your comment!
Please enter your name here

Latest Articles